PPARs: altering clinical responses in Type 2 diabetes and atherosclerosis. Introduction.
作者信息
Plutzky Jorge
机构信息
Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
出版信息
Clin Cardiol. 2004 Jul;27(7 Suppl 4):IV1-2. doi: 10.1002/clc.4960271602.
Abstract
摘要
相似文献
1
PPARs: altering clinical responses in Type 2 diabetes and atherosclerosis. Introduction.过氧化物酶体增殖物激活受体：改变2型糖尿病和动脉粥样硬化的临床反应。引言。
Clin Cardiol. 2004 Jul;27(7 Suppl 4):IV1-2. doi: 10.1002/clc.4960271602.
2
Peroxisome proliferator-activated receptors as therapeutic targets in inflammation.
J Am Coll Cardiol. 2003 Nov 19;42(10):1764-6. doi: 10.1016/j.jacc.2003.08.017.
3
Will the potential of peroxisome proliferator-activated receptor agonists be realized in the clinical setting?过氧化物酶体增殖物激活受体激动剂的潜力会在临床环境中得以实现吗？
Clin Cardiol. 2004 Jul;27(7 Suppl 4):IV3-10. doi: 10.1002/clc.4960271603.
4
PPARgamma--an important regulator of monocyte/macrophage function.
Arch Immunol Ther Exp (Warsz). 2003;51(4):219-26.
5
The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis.
Am J Cardiol. 2003 Aug 18;92(4A):34J-41J. doi: 10.1016/s0002-9149(03)00614-3.
6
PPARS in inflammation, atherosclerosis and thrombosis.过氧化物酶体增殖物激活受体在炎症、动脉粥样硬化和血栓形成中的作用
J Cardiovasc Risk. 2001 Aug;8(4):187-94. doi: 10.1177/174182670100800402.
7
The peroxisome proliferator-activated receptor(PPARgamma) as a regulator of monocyte/macrophage function.过氧化物酶体增殖物激活受体（PPARγ）作为单核细胞/巨噬细胞功能的调节因子。
J Leukoc Biol. 1999 Nov;66(5):733-9. doi: 10.1002/jlb.66.5.733.
8
PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis.过氧化物酶体增殖物激活受体激动剂作为人类T淋巴细胞中的抗炎介质：对动脉粥样硬化和移植相关动脉硬化的影响
Circ Res. 2002 Apr 5;90(6):703-10. doi: 10.1161/01.res.0000014225.20727.8f.
9
Antiinflammatory properties of PPARgamma agonists following ischemia.
Drug News Perspect. 2004 May;17(4):229-36. doi: 10.1358/dnp.2004.17.4.829049.
10
On par with PPARs.与过氧化物酶体增殖物激活受体（PPARs）相当。
Trends Genet. 2001 Jun;17(6):310-12. doi: 10.1016/s0168-9525(01)02317-4.
本文引用的文献
1
Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.噻唑烷二酮类药物的使用、液体潴留与充血性心力衰竭：美国心脏协会和美国糖尿病协会的共识声明。2003年10月7日。
Circulation. 2003 Dec 9;108(23):2941-8. doi: 10.1161/01.CIR.0000103683.99399.7E.
2
Adhesion molecules and atherosclerosis.黏附分子与动脉粥样硬化。
Atherosclerosis. 2003 Oct;170(2):191-203. doi: 10.1016/s0021-9150(03)00097-2.
3
Peroxisome proliferator activated receptor gamma and its activation in the treatment of insulin resistance and atherosclerosis: issues and opportunities.
Curr Opin Cardiol. 2003 Nov;18(6):479-85. doi: 10.1097/00001573-200311000-00009.
4
Medicine. PPARs as therapeutic targets: reverse cardiology?医学。过氧化物酶体增殖物激活受体作为治疗靶点：逆向心脏病学？
Science. 2003 Oct 17;302(5644):406-7. doi: 10.1126/science.1091172.
5
Insulin resistance and chronic cardiovascular inflammatory syndrome.胰岛素抵抗与慢性心血管炎症综合征。
Endocr Rev. 2003 Jun;24(3):278-301. doi: 10.1210/er.2002-0010.
6
Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets.2型糖尿病与胰岛素抵抗中的动脉粥样硬化：机制联系与治疗靶点
J Diabetes Complications. 2002 Nov-Dec;16(6):401-15. doi: 10.1016/s1056-8727(02)00202-7.
7
Diabetes and atherosclerosis: epidemiology, pathophysiology, and management.糖尿病与动脉粥样硬化：流行病学、病理生理学及管理
JAMA. 2002 May 15;287(19):2570-81. doi: 10.1001/jama.287.19.2570.
8
ATP-binding cassette (ABC) transporters in atherosclerosis.动脉粥样硬化中的ATP结合盒（ABC）转运蛋白
Curr Atheroscler Rep. 2002 May;4(3):243-51. doi: 10.1007/s11883-002-0026-2.
9
Inflammation and atherosclerosis.炎症与动脉粥样硬化。
Circulation. 2002 Mar 5;105(9):1135-43. doi: 10.1161/hc0902.104353.
10
Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly.基质金属蛋白酶在血管重塑和动脉粥样硬化形成中的作用：有益、有害与丑陋之处。
Circ Res. 2002 Feb 22;90(3):251-62.
Zotero 插件